Target- |
Mechanismkinase inhibitor |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals? HPV-16/18 VLP/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy female subjects aged 10 ? 14 years. - HPV-013
100 Clinical Results associated with GlaxoSmithKline SA (Spain)
0 Patents (Medical) associated with GlaxoSmithKline SA (Spain)
100 Deals associated with GlaxoSmithKline SA (Spain)
100 Translational Medicine associated with GlaxoSmithKline SA (Spain)